Gross Margin

Fresh off its IPO, iOThree is pushing AI and certified digital tools. Can its innovation engine and Asian expansion overcome market headwinds?

As Uxin prepares to report Q3 results, all eyes are on its ambitious superstore strategy and whether it can drive profitability in a complex market.

Genmab's $8 billion acquisition of Merus isn't just a deal; it's a bold strategy to own its destiny and dominate the future of oncology therapeutics.

Lument Finance Trust's latest dividend boasts an attractive yield, but recent adjustments raise questions about the health of commercial real estate.

BrightView Holdings declared its eighth straight cash dividend, a move signaling financial discipline even as it navigates revenue challenges and stock volatility.

A routine filing reveals a major strategic play. See how BridgeBio Oncology uses special equity grants to attract top minds in the fierce race for a cancer cure.

Argan's repeated dividend hikes and record backlog reflect deep confidence, positioning it to capitalize on surging demand for critical energy infrastructure.

As TD SYNNEX prepares its full-year report, the results will be a crucial test of its AI strategy and a key indicator for the entire IT ecosystem.

KBRA rates a $328M mortgage trust with significant 'non-prime' loans, signaling a boom in a market segment that balances risk with investor demand.

A key industry award for tech partner CI&T reveals how AI and data are the new foundations of high-end retail. Who is building the future of luxury?

MMTEC dodged delisting, but a one-year Nasdaq monitor and a history of reverse splits raise questions about its long-term viability on US exchanges.

CardCash's record November reveals a major shift in consumer behavior, where shoppers are using discounted gift cards as a tool to fight inflation.

Beyond its first-ever dividend, Covalon's true story is one of clinical innovation driving record sales, navigating market shifts, and funding global growth.

The industrial giant secured a rare dual 'A' rating from CDP. We decode what this means for its strategy, competitors, and ESG-focused investors.

With two key drug approvals, Sanofi isn't just treating rare diseases in China; it's executing a playbook that redefines market entry and dominance.

Beyond the headlines of a $592M debt reduction, McGraw Hill is executing a dual strategy: fortifying its finances to fund a digital and AI-driven future.

The 2025 proxy season saw record director support as investors prioritized financials, yet dissent over executive pay signals a new battleground.

A struggling interactive entertainment firm bets its future on gold, targeting Malaysia's booming market. A look at the high-stakes pivot shaking up BHAT.

Unisync Corp. engineered a dramatic return to profitability. We explore the deep operational changes and strategic wins that fueled this impressive turnaround.

The fight for STAAR Surgical heats up. Alcon's new $1.6B offer isn't enough for its largest shareholder, who alleges a deeply conflicted sales process.